SAG
RVMD icon

SageView Advisory Group’s Revolution Medicines RVMD Stock Holding History

SageView Advisory Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-190
Closed -$15.1K – 2059
2025
Q4 		$15.1K Buy
+190
New +$12.5K ﹤0.01% 1557

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SageView Advisory Group's RVMD Position: Q1 2026 in Review

SageView Advisory Group sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 190 shares — an estimated $15.1K sold.

SageView Advisory Group first reported a position in RVMD in Q4 2025 and held it in 1 quarter. The position peaked at $15.1K in Q4 2025. 514 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • SageView Advisory Group reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 190 Revolution Medicines shares in Q1 2026, an estimated $15.1K.
  • SageView Advisory Group first reported a position in Revolution Medicines in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Revolution Medicines position peaked at $15.1K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.